AB0461 Long-term use of adalimumab as monotherapy following attainment of low-disease activity: Subanalysis of the open-label extension of premier

Abstract

BackgroundThere has been increased interest in understanding whether biologics can be safely withdrawn from patients (pts) receiving combination therapy with MTX once a clinical target has been achieved. The ability...